JAB-26766 / Jacobio Pharma - LARVOL DELTA

JAB-26766: A small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity (AACR 2024) - "JAB-26766 is an orally bioavailable, highly potent, and selective PARP7 inhibitor that shows early promising anti-tumor activities."

IO biomarker • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CXCL10 • IFNB1 • PARP2 • TIPARP

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting (PRNewswire) - "JAB-26766 is a potent, orally bioavailable PARP7 inhibitor with >1800-fold selectivity on PARP7 over PARP2. JAB-26766 as a single agent shows potent in vivo anti-tumor activities, which can be further enhanced through combination with STING agonist or anti-PD-1 mAb."

Preclinical • Oncology • Solid Tumor

Jacobio Pharma Announces 2023 Annual Results (PRNewswire) - "Anti-CD73 humanized monoclonal antibody JAB-BX102: RP2D is anticipated to be determined in Q2 2024. The preclinical study of JAB-2485 was presented at the 2023 AACR; PARP7 inhibitor JAB-26766: Preclinical data will be presented at the AACR Annual Meeting 2024."

Preclinical • Trial status • Oncology • Solid Tumor

Changes in Hong Kong stocks | Jiakesi-B (01167) rose more than 4% and the clinical trial of self-developed PARP7 inhibitor JAB-26766 was approved [Google translation] (Sina Corp) - "On the news, JACOS announced that the company's self-developed PARP7 inhibitor JAB-26766 has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for clinical trials of new drugs (IND), and will conduct I/ Phase IIa clinical trial in advanced solid tumors. It is reported that PARP7 inhibitors target the tumor immune (I/O) signaling pathway and can be used to treat various solid tumors such as squamous non-small cell lung cancer and head and neck squamous cell carcinoma."

New P1/2 trial • Head and Neck Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Jacobio Pharma Announces 2022 Annual Results (PRNewswire) - "Jacobio has submitted the IND applications of JAB-BX300 (LIF mAb) to the NMPA in January 2023. The IND applications of JAB-23400 (KRASmulti inhibitor), JAB-30300 (P53 Y220C corrector) and JAB-26766 (PARP7 inhibitor) will be submitted this year."

New trial • Oncology